In a heterologous treatment sequence with an adenoviral TAA-endoding vaccine and an oncolytic VSV tumor expressing the same antigen significantly enhanced tumor-directed CD8 T cell immune responses compared to single treatments. The gene discussed is CD8A; the disease is neoplasm.